Andrea Sartore-Bianchi
Andrea Sartore-Bianchi
Clinical Molecular Oncology, Niguarda Cancer Center, Milano - Italy
Verified email at ospedaleniguarda.it - Homepage
TitleCited byYear
Detection of circulating tumor DNA in early-and late-stage human malignancies
C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ...
Science translational medicine 6 (224), 224ra24-224ra24, 2014
20182014
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective …
W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ...
The lancet oncology 11 (8), 753-762, 2010
18572010
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
F Di Nicolantonio, M Martini, F Molinari, A Sartore Bianchi, S Arena, ...
18002008
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ...
Nature 486 (7404), 532, 2012
12602012
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni, S Veronese, S Benvenuti, G Marrapese, A Sartore-Bianchi, ...
The lancet oncology 6 (5), 279-286, 2005
10412005
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti–epidermal growth factor receptor antibody therapies
S Benvenuti, A Sartore-Bianchi, F Di Nicolantonio, C Zanon, M Moroni, ...
Cancer research 67 (6), 2643-2648, 2007
9052007
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies
A Sartore-Bianchi, M Martini, F Molinari, S Veronese, M Nichelatti, ...
Cancer research 69 (5), 1851-1857, 2009
7602009
Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
W De Roock, DJ Jonker, F Di Nicolantonio, A Sartore-Bianchi, D Tu, ...
Jama 304 (16), 1812-1820, 2010
6692010
Biomarkers predicting clinical outcome of epidermal growth factor receptor–targeted therapy in metastatic colorectal cancer
S Siena, A Sartore-Bianchi, F Di Nicolantonio, J Balfour, A Bardelli
Journal of the National Cancer Institute 101 (19), 1308-1324, 2009
6022009
A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer
A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D Corà, ...
Cancer discovery 1 (6), 508-523, 2011
5912011
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ...
Nature medicine 21 (7), 795, 2015
5092015
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ...
Cancer discovery 3 (6), 658-673, 2013
4402013
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab
A Sartore-Bianchi, M Moroni, S Veronese, C Carnaghi, E Bajetta, G Luppi, ...
Journal of Clinical Oncology 25 (22), 3238-3245, 2007
3612007
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of …
A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ...
The Lancet Oncology 17 (6), 738-746, 2016
3162016
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer
A Sartore-Bianchi, F Di Nicolantonio, M Nichelatti, F Molinari, S De Dosso, ...
PloS one 4 (10), e7287, 2009
2732009
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer
S Artale, A Sartore Bianchi, SM Veronese, V Gambi, CS Sarnataro, ...
2482008
The genomic landscape of response to EGFR blockade in colorectal cancer
A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou, B Lupo, M Sausen, ...
Nature 526 (7572), 263, 2015
2262015
Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution
S Misale, F Di Nicolantonio, A Sartore-Bianchi, S Siena, A Bardelli
Cancer discovery 4 (11), 1269-1280, 2014
2252014
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)
A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ...
Cancer discovery 7 (4), 400-409, 2017
2122017
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer
S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ...
Science translational medicine 6 (224), 224ra26-224ra26, 2014
1962014
The system can't perform the operation now. Try again later.
Articles 1–20